Cargando…
Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219932/ https://www.ncbi.nlm.nih.gov/pubmed/35676464 http://dx.doi.org/10.1038/s41433-022-02130-2 |
| _version_ | 1785049114506952704 |
|---|---|
| author | Lally, David R. Loewenstein, Anat Arnold, Jennifer J. Yang, Yit C. Gedif, Kinfemichael Best, Catherine Patel, Hersh Tadayoni, Ramin Heier, Jeffrey S. |
| author_facet | Lally, David R. Loewenstein, Anat Arnold, Jennifer J. Yang, Yit C. Gedif, Kinfemichael Best, Catherine Patel, Hersh Tadayoni, Ramin Heier, Jeffrey S. |
| author_sort | Lally, David R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10219932 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102199322023-05-28 Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies Lally, David R. Loewenstein, Anat Arnold, Jennifer J. Yang, Yit C. Gedif, Kinfemichael Best, Catherine Patel, Hersh Tadayoni, Ramin Heier, Jeffrey S. Eye (Lond) Correction Nature Publishing Group UK 2022-06-08 2023-06 /pmc/articles/PMC10219932/ /pubmed/35676464 http://dx.doi.org/10.1038/s41433-022-02130-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Lally, David R. Loewenstein, Anat Arnold, Jennifer J. Yang, Yit C. Gedif, Kinfemichael Best, Catherine Patel, Hersh Tadayoni, Ramin Heier, Jeffrey S. Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies |
| title | Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies |
| title_full | Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies |
| title_fullStr | Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies |
| title_full_unstemmed | Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies |
| title_short | Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies |
| title_sort | correction: efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the hawk and harrier studies |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219932/ https://www.ncbi.nlm.nih.gov/pubmed/35676464 http://dx.doi.org/10.1038/s41433-022-02130-2 |
| work_keys_str_mv | AT lallydavidr correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT loewensteinanat correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT arnoldjenniferj correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT yangyitc correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT gedifkinfemichael correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT bestcatherine correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT patelhersh correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT tadayoniramin correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies AT heierjeffreys correctionefficacyandsafetyofbrolucizumabversusafliberceptineyeswithearlypersistentretinalfluid96weekoutcomesfromthehawkandharrierstudies |